November 3, 2025
Frederick, MD – Jecho Laboratories, Inc. will present emerging preclinical data on JLC059, a novel GPC3/PD-L1 bispecific antibody drug conjugate (bsADC) at the 16th Annual World ADC Congress. GPC3 is a tumor-associated antigen highly expressed in liver and other solid tumors, while PD-L1 plays a key role in suppressing immune responses. JLC059 is composed of a fast-internalizing anti-GPC3 arm and a non-internalizing anti-PD-L1 arm, which enables targeted delivery of a cytotoxic payload to tumors and disrupts immunosuppressive signaling while minimizing toxicity to immune cells.
The World ADC Congress will be held November 3-6, 2025 in San Diego, CA.
Details on the presentation are below:
Abstract 8: JLC059, a novel GPC3/PD-L1 bsADC integrating checkpoint inhibition for enhanced anti-tumor activity
- Abstract Presentation Number: 8
- Session Time: Tuesday, November 24, 2025 viewing 10:00 a.m. – 5:00 p.m. PST
- Location: Town & Country, San Diego